Alcobra discusses mechanism of action for proprietary ADHD treatment


Metadoxine ER "appears to enhance the ability of cells to correct abnormal signaling pathways that may be involved with cognitive impairment," Alcobra (ADHD) says, reporting results from preclinical studies designed to evaluate the drug's mechanism of action.

MG01CI does not "increase levels of neurotransmitters in the brain such as dopamine, norepinephrine and serotonin," Alcobra adds.

The drug is the company's proprietary treatment for cognitive dysfunctions, such as ADHD and Fragile X Syndrome.

The company's Chief Medical Officer is "eager to move forward with additional clinical trials." (PR)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs